The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

Q4 2024 Management View CEO Albert Bourla highlighted Pfizer's strong execution in 2024, emphasizing the successful integration of Seagen, which has positioned Pfizer as a leading oncology company. He ...

Jeffrey Smith’s Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund’s new buys during the fourth quarter ...

Shareholders of Pfizer may learn more about this investigation by contacting Berger Montague: Radha Raghavan at rraghavan@bm.net or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bm.net or (215) ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

That mission is getting a big boost from the late John Mitchell, a longtime supporter and Pfizer Global Manufacturing executive. “… then he goes and has this, certainly, very celebrated ...

Pfizer has resolved a lawsuit by a conservative group that alleged that a fellowship program that the drugmaker established to boost the pipeline of Black, Latino and Native American people in ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...